# Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects

> **NCT05638126** · PHASE1 · UNKNOWN · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** HRS-1780 table or placebo
- **DRUG:** HRS-1780 table or placebo
- **DRUG:** HRS-1780 table or placebo

## Key facts

- **NCT ID:** NCT05638126
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-02
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638126, "Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05638126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*